Trial · NCT00391872
Trial comparisons16
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 16 of 16
Download this page as JSON| Comparison | Source |
|---|---|
| TICAGRELOR vs CLOPIDOGREL: Participants With Death From Vascular Causes | Trial comparisons |
TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events. | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With MI Event | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Stroke | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Death From Any Cause | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Any Major Bleeding Event | Trial comparisons |
TICAGRELOR vs CLOPIDOGREL: Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Major or Minor Bleeding | Trial comparisons |
TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Non-procedural Major Bleeding | Trial comparisons |
| TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00391872/comparisons